805 related articles for article (PubMed ID: 30882240)
21. Effect of Canagliflozin Compared With Sitagliptin on Serum Lipids in Patients with Type 2 Diabetes Mellitus and Heart Failure with Reduced Ejection Fraction: A Post-Hoc Analysis of the CANA-HF Study.
Dixon DL; Billingsley HE; Canada JM; Trankle CR; Kadariya D; Cooke R; Hart L; Van Tassell B; Abbate A; Carbone S
J Cardiovasc Pharmacol; 2021 Sep; 78(3):407-410. PubMed ID: 34132690
[TBL] [Abstract][Full Text] [Related]
22. Effect of canagliflozin use on body weight and blood pressure at one-year follow-up: A systematic review and meta-analysis.
Khan MS; Usman MS; Siddiqi TJ; Memon MM; Shah SJ; Khan SS
Eur J Prev Cardiol; 2019 Oct; 26(15):1680-1682. PubMed ID: 30755019
[No Abstract] [Full Text] [Related]
23. Effect of canagliflozin on white blood cell counts in patients with type 2 diabetes and heart failure: A subanalysis of the randomized CANDLE trial.
Tanaka A; Imai T; Shimabukuro M; Nakamura I; Matsunaga K; Ozaki Y; Minamino T; Sata M; Node K;
J Diabetes Investig; 2022 Dec; 13(12):1990-1999. PubMed ID: 36114704
[TBL] [Abstract][Full Text] [Related]
24. The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: The CANA-HF study.
Carbone S; Billingsley HE; Canada JM; Bressi E; Rotelli B; Kadariya D; Dixon DL; Markley R; Trankle CR; Cooke R; Rao K; B Shah K; Medina de Chazal H; Chiabrando JG; Vecchié A; Dell M; L Mihalick V; Bogaev R; Hart L; Van Tassell BW; Arena R; Celi FS; Abbate A
Diabetes Metab Res Rev; 2020 Nov; 36(8):e3335. PubMed ID: 32415802
[TBL] [Abstract][Full Text] [Related]
25. Clinical potential of canagliflozin in cardiovascular risk reduction in patients with type 2 diabetes.
Skelley JW; Carter BS; Roberts MZ
Vasc Health Risk Manag; 2018; 14():419-428. PubMed ID: 30573964
[TBL] [Abstract][Full Text] [Related]
26. Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial.
Sarraju A; Li J; Cannon CP; Chang TI; Agarwal R; Bakris G; Charytan DM; de Zeeuw D; Greene T; Heerspink HJL; Levin A; Neal B; Pollock C; Wheeler DC; Yavin Y; Zhang H; Zinman B; Perkovic V; Jardine M; Mahaffey KW
Am Heart J; 2021 Mar; 233():141-148. PubMed ID: 33358942
[TBL] [Abstract][Full Text] [Related]
27. Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.
Tanaka A; Inoue T; Kitakaze M; Oyama J; Sata M; Taguchi I; Shimizu W; Watada H; Tomiyama H; Ako J; Sakata Y; Anzai T; Uematsu M; Suzuki M; Eguchi K; Yamashina A; Saito Y; Sato Y; Ueda S; Murohara T; Node K
Cardiovasc Diabetol; 2016 Apr; 15():57. PubMed ID: 27044332
[TBL] [Abstract][Full Text] [Related]
28. Empagliflozin (Jardiance) for heart failure with reduced ejection fraction.
Med Lett Drugs Ther; 2021 Nov; 63(1636):171-172. PubMed ID: 35085205
[No Abstract] [Full Text] [Related]
29. Sodium-Glucose Cotransporter-2 inhibitors are potential therapeutic agents for treatment of non-diabetic heart failure patients.
Nakagawa Y; Kuwahara K
J Cardiol; 2020 Aug; 76(2):123-131. PubMed ID: 32340780
[TBL] [Abstract][Full Text] [Related]
30. SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction.
Jhund PS
Heart Fail Clin; 2022 Oct; 18(4):579-586. PubMed ID: 36216487
[TBL] [Abstract][Full Text] [Related]
31. Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality.
Savarese G; Sattar N; Januzzi J; Verma S; Lund LH; Fitchett D; Zeller C; George JT; Brueckmann M; Ofstad AP; Inzucchi SE; Wanner C; Zinman B; Butler J
Circulation; 2019 Mar; 139(11):1458-1460. PubMed ID: 30855996
[No Abstract] [Full Text] [Related]
32. Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology.
Seferović PM; Fragasso G; Petrie M; Mullens W; Ferrari R; Thum T; Bauersachs J; Anker SD; Ray R; Çavuşoğlu Y; Polovina M; Metra M; Ambrosio G; Prasad K; Seferović J; Jhund PS; Dattilo G; Čelutkiene J; Piepoli M; Moura B; Chioncel O; Ben Gal T; Heymans S; de Boer RA; Jaarsma T; Hill L; Lopatin Y; Lyon AR; Ponikowski P; Lainščak M; Jankowska E; Mueller C; Cosentino F; Lund L; Filippatos GS; Ruschitzka F; Coats AJS; Rosano GMC
Eur J Heart Fail; 2020 Sep; 22(9):1495-1503. PubMed ID: 32618086
[TBL] [Abstract][Full Text] [Related]
33. Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes.
Li J; Woodward M; Perkovic V; Figtree GA; Heerspink HJL; Mahaffey KW; de Zeeuw D; Vercruysse F; Shaw W; Matthews DR; Neal B
JACC Heart Fail; 2020 Jan; 8(1):57-66. PubMed ID: 31676303
[TBL] [Abstract][Full Text] [Related]
34. Potential impact of SGLT2 inhibitors on left ventricular diastolic function in patients with diabetes mellitus.
Tanaka H; Hirata KI
Heart Fail Rev; 2018 May; 23(3):439-444. PubMed ID: 29330646
[TBL] [Abstract][Full Text] [Related]
35. [Outcome studies on SGLT-2 inhibitors].
Seufert J; Laubner K
Internist (Berl); 2019 Sep; 60(9):903-911. PubMed ID: 31375850
[TBL] [Abstract][Full Text] [Related]
36. Does canagliflozin decrease natriuretic peptide levels in patients with diabetes and heart failure?
Martín E; Castillo JC; González-Manzanares R; López Aguilera J; Perea J; Anguita M
Cardiol J; 2022; 29(1):166-169. PubMed ID: 34931694
[No Abstract] [Full Text] [Related]
37. Effect of Canagliflozin on Heart Function Involving Ketone Bodies in Patients with Type 2 Diabetes.
Kutoh E; Hayashi J
Drug Res (Stuttg); 2019 May; 69(5):297-300. PubMed ID: 30296805
[TBL] [Abstract][Full Text] [Related]
38. Fanconi syndrome associated with SGLT2 inhibitor, canagliflozin.
Esprit DH; Koratala A
Nephrology (Carlton); 2018 May; 23(5):493. PubMed ID: 29696765
[No Abstract] [Full Text] [Related]
39. Treating Heart Failure With Antihyperglycemic Medications: Is Now the Right Time?
Testani JM; Inzucchi SE; Voors AA
Circulation; 2019 May; 139(21):2383-2385. PubMed ID: 31107618
[No Abstract] [Full Text] [Related]
40. The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial.
Spertus JA; Birmingham MC; Nassif M; Damaraju CV; Abbate A; Butler J; Lanfear DE; Lingvay I; Kosiborod MN; Januzzi JL
Nat Med; 2022 Apr; 28(4):809-813. PubMed ID: 35228753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
